The FDA has faulted AbbVie’s promotion of the migraine drug Ubrelvy, calling the company out for an ad featuring Serena ...

The next frame shows the Ubrelvy logo in the backstage hallway along with a blue lit path. Frames six to seven then show Serena Williams walking down the blue lit path, no longer exhibiting migraine ...

The newer and more expensive drugs rimegepant and ubrogepant — as well as another called lasmiditan, which can have drowsy ...

The Food and Drug Administration recently intervened regarding a migraine medication ad featuring tennis superstar Serena ...

AbbVie’s migraine drug Ubrelvy (ubrogepant) is slated to be the top-selling drug in the migraine space in 2033 across the ...

In the ad for oral CGRP inhibitor Ubrelvy (ubrogepant), Williams is depicted as suffering from a migraine while in a talk ...

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

New migraine drugs less effective than traditional painkillers, triptans, according to global analysis in The BMJ.

The U.S. Food and Drug Administration is taking North Chicago-based drugmaker AbbVie to task, warning in a recent letter that ...

A migraine medicine once-endorsed by Serena Williams has come under fire amid claims advertisements oversold it's usefulness.

Ubrelvy (ubrogepant) is a prescription oral tablet that’s used for fast-acting relief of migraine symptoms in adults. Ubrelvy may not be safe to take while pregnant or breastfeeding. If you can ...